A leader in the discovery of oral direct-acting antiviral therapies.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in MORNINGSKY, a global multi-center Phase 3 clinical trial for the treatment of patients with mild or moderate COVID-19 in an outpatient setting. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus.

Learn More


Innovative discovery and efficient development of potentially transformative therapies for patients with life-threatening viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.


The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.

A network of hubs and spokes is suspended, representing the idea of a modular platform.


AT-527 addresses the key challenges of the COVID-19 pandemic and beyond.

For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.

While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus. To treat patients who are waiting to or do not want to be immunized and for patients for whom the vaccine does not create protective immunity, direct-acting antivirals are and will remain an essential complement to vaccines.

AT-527 is an oral, direct-acting antiviral drug candidate.

AT-527 is being evaluated for easy and early administration to reduce burden and duration of disease. AT-527 has the potential to be used for pre- and post-exposure prophylaxis, to reduce transmission and to impact long-term COVID sequelae.

Similar to Tamiflu®

Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®)

Significant advantages vs antibodies

Significant advantages vs antibodies:

  • convenient for patients and healthcare workers
  • global reach
  • manufacture
  • scale-up
  • cost
Effective vs. mutations

Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants

anticipated to be effective again st future coronaviruses

Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated


Follow our progress.

See updates on AT-527, other Atea product candidates and company news.

Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference

BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized Setting AT-527 is Being Studied in Multiple Clinical Studies, Including Global Phase 2 MOONSONG and Phase 3 MORNINGSKY Trials, with Results Expected

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

Milestone in the amount of $50 million realized BOSTON, June 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced that it